Informing optimal dosing of the future antimalarial, artemether-lumefantrine plus amodiaquine, in key neglected target populations of children with severe acute malnutrition and adults living with HIV
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
Emerging Global Leader
Project Information in NIH RePORTER
Informing optimal dosing of the future antimalarial, artemether-lumefantrine plus amodiaquine, in key neglected target populations of children with severe acute malnutrition and adults living with HIV
Principal Institution
Kamuzu University of Health Sciences
Principal Investigator(s) (PI)
Banda, Clifford George
Project Contact Information
Email:
cgbanda@mlw.mw
Year(s) Awarded
2024-2029
Country
Malawi
Project Description
Given the emerging resistance of malaria parasites to first-line artemisinin-based combination therapy (ACT), new antimalarial drug combinations are urgently needed. Triple ACTs (TACTs) have been identified as the most feasible and affordable alternative solution to ACTs. The combination of artemether with both lumefantrine and amodiaquine is an example of a TACT that benefits from the longer-acting partner drugs, lumefantrine and amodiaquine, having different and potentially opposing resistance mechanisms.
However, children with severe acute malnutrition and adults living with HIV are two key subgroups that have been excluded from early dose optimisation studies and Phase 3 studies of this promising TACT. This project will investigate artemether-lumefantrine plus amodiaquine’s disposition and safety in these two key target subgroups.
Related World Regions / Countries
Related Global Health Research Topics